Wall Street analysts expect Dextera Surgical Inc. (NASDAQ:DXTR) to report sales of $620,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dextera Surgical’s earnings, with the lowest sales estimate coming in at $570,000.00 and the highest estimate coming in at $670,000.00. Dextera Surgical reported sales of $470,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 31.9%. The business is expected to report its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Dextera Surgical will report full year sales of $620,000.00 for the current fiscal year, with estimates ranging from $3.75 million to $3.87 million. For the next fiscal year, analysts forecast that the business will report sales of $7.21 million per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Dextera Surgical.

Dextera Surgical (NASDAQ:DXTR) last issued its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.29). The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.03 million.

A number of research analysts recently commented on DXTR shares. Ladenburg Thalmann Financial Services started coverage on Dextera Surgical in a research report on Wednesday, August 16th. They issued a “buy” rating and a $0.80 price target on the stock. Zacks Investment Research upgraded Dextera Surgical from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Wedbush decreased their price target on Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating on the stock in a research report on Wednesday, July 12th.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. bought a new position in shares of Dextera Surgical in the second quarter worth $100,000. Virtu KCG Holdings LLC increased its position in shares of Dextera Surgical by 1,380.6% in the second quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 344,933 shares during the period. Finally, Broadfin Capital LLC increased its position in shares of Dextera Surgical by 64.7% in the second quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock worth $296,000 after purchasing an additional 388,080 shares during the period. Institutional investors own 6.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/13/dextera-surgical-inc-dxtr-expected-to-post-quarterly-sales-of-620000-00.html.

About Dextera Surgical

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dextera Surgical (NASDAQ:DXTR)

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.